Open Access Article

Peripheral Neuropathy Associated With Novel Therapies in Patients With Multiple Myeloma: Consensus Statement of the IMF Nurse Leadership Board

Joseph D. Tariman

Ginger Love

Emily J. McCullagh

Stacey Sandifer

peripheral neuropathies
CJON 2008, 12(3), 29-35. DOI: 10.1188/08.CJON.S1.29-35

The novel therapies thalidomide and bortezomib can cause peripheral neuropathy, a challenging adverse event that can affect quality of life and compromise optimal treatment for patients with multiple myeloma. At baseline, patients should be evaluated for signs and symptoms of peripheral neuropathy with a neurotoxicity assessment tool and educated about the symptoms and the importance of reporting them. Signs, symptoms, and the ability to perform activities of daily living should be evaluated regularly so that appropriate interventions can be employed if necessary. Specific management strate-gies for peripheral neuropathy are based on the grade of severity and on signs and symptoms; strategies include dose and schedule modifications, pharmacologic interventions, nonpharmacologic approaches, and patient education.

Jump to a section


    American Cancer Society. (2005). Pain management pocket tool. Retrieved September 10, 2007, from
    Anderson, K., Richardson, P., Chanan-Khan, A., Schlossman, R., Munshi, N., Oaklander, A., et al. (2006). Single agent bortezomib in previously untreated multiple myeloma (MM): Results of a phase II multicenter study. 2006 ASCO Annual Meeting Proceedings Part 1 [Abstract]. Journal of Clinical Oncology, 24(18, Suppl.), 7504.
    Richardson, P. G., & Anderson, K. (2006). Thalidomide and dexamethasone: A new standard of care for initial therapy in multiple myeloma. Journal of Clinical Oncology, 24(3), 334-335.
    Richardson, P. G., Blood, E., Mitsiades, C. S., Jagannath, S., Zeldenrust, S. R., Alsina, M., et al. (2006). A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 108(10), 3458-3464.
    Richardson, P. G., Briemberg, H., Jagannath, S., Wen, P. Y., Barlogie, B., Berenson, J., et al. (2006). Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. Journal of Clinical Oncology, 24(19), 3113-3120.
    Richardson, P. G., Briemberg, H., Jagannath, S., Wen, P. Y., Schlossman, R. L., Doss, D., et al. (2007). Reversible peripheral neuropathy during treatment of multiple myeloma with bortezomib: A case history. American Journal of Hematology/Oncology, 6(4), 189-192.
    Richardson, P. G., Hideshima, T., Mitsiades, C., & Anderson, K. C. (2007). The emerging role of novel therapies for the treatment of relapsed myeloma. Journal of the National Comprehensive Cancer Network, 5(2), 149-162.
    Ropper, A. H., & Gorson, K. C. (1998). Neuropathies associated with paraproteinemia. New England Journal of Medicine, 338(22), 1601-1607.
    Dispenzieri, A., & Kyle, R. A. (2005). Neurological aspects of multiple myeloma and related disorders. Best Practice and Research Clinical Haematology, 18(4), 673-688.
    Doss, D. S. (2006). Advances in oral therapy in the treatment of multiple myeloma. Clinical Journal of Oncology Nursing, 10(4), 514-520.
    Endo Pharmaceuticals. (2006). Lidoderm® (lidocaine patch 5%) [Package insert]. Chadds Ford, PA: Author.
    Fahdi, I. E., Gaddam, V., Saucedo, J. F., Kishan, C. V., Vyas, K., Deneke, M. G., et al. (2004). Bradycardia during therapy for multiple myeloma with thalidomide. American Journal of Cardiology, 93(8), 1052-1055.
    Ghobrial, J., Ghobrial, I. M., Mitsiades, C., Leleu, X., Hatjiharissi, E., Moreau, A. S., et al. (2007). Novel therapeutic avenues in myeloma: Changing the treatment paradigm. Oncology, 21(7), 785-792.
    Lonial, S. (2007). Balancing efficacy and toxicity: Addressing peripheral neuropathy and enhancing quality of life. American Journal of Hematology/Oncology, 6(4), 194-196.
    Manochakian, R., Miller, K. C., & Chanan-Khan, A. A. (2007). Clinical impact of bortezomib in frontline regimens for patients with multiple myeloma. Oncologist, 12(8), 978-990.
    Marrs, J., & Newton, S. (2003). Updating your peripheral neuropathy "know-how." Clinical Journal of Oncology Nursing, 7(3), 299-303.
    Mileshkin, L., Stark, R., Day, B., Seymour, J. F., Zeldis, J. B., & Prince, H. M. (2006). Development of neuropathy in patients with myeloma treated with thalidomide: Patterns of occurrence and the role of electrophysiologic monitoring. Journal of Clinical Oncology, 24(27), 4507-4514.
    Millennium Pharmaceuticals, Inc. (2007). Velcade® (bortezomib) [Package insert]. Cambridge, MA: Author.
    National Cancer Institute. (2006). Common Terminology Criteria for Adverse Events v.3.0. Retrieved August 8, 2007, from
    National Comprehensive Cancer Network. (2007). NCCN Clinical Practice Guidelines in Oncology™: Adult cancer pain [v.1.2007]. Retrieved September 20, 2007, from
    National Comprehensive Cancer Network & American Cancer Society. (2005). Cancer pain: Treatment guidelines for patients. Retrieved September 20, 2007, from
    National Institute of Neurological Disorders and Stroke. (2007). Peripheral neuropathy fact sheet. Retrieved October 23, 2007, from
    Oncology Nursing Society. (2004). Cancer pain management [Position statement]. Retrieved November 17, 2006, from
    Orlowski, R. Z., Stinchcombe, T. E., Mitchell, B. S., Shea, T. C., Baldwin, A. S., Stahl, S., et al. (2002). Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. Journal of Clinical Oncology, 20(22), 4420-4427.
    Plasmati, R., Pastorelli, F., Cabo, M., Petracci, E., Zamagni, E., Tosi, P., et al. (2007). Neuropathy in multiple myeloma treated with thalidomide: A prospective study. Neurology, 69(6), 573-581.
    Armstrong, T., Almadrones, L., & Gilbert, M. R. (2005). Chemotherapy-induced peripheral neuropathy. Oncology Nursing Forum, 32(2), 305-311.
    Bertolotti, P., Bilotti, E., Colson, K., Curran, K., Doss, D., Faiman, B., et al. (2007). Nursing guidelines for enhanced patient care. Haematologica, 92(Suppl. 2), 211.
    Bertolotti, P., Bilotti, E., Colson, K., Curran, K., Doss, D., Faiman, B., et al. (2008). Management of side effects of novel therapies for multiple myeloma: Consensus statements developed by the International Myeloma Foundation's Nurse Leadership Board. Clinical Journal of Oncology Nursing, 12(3, Suppl.), 9-12.
    Calhoun, E. A., Fishman, D. A., Roland, P. Y., Lurain, J. R., Chang, C. H., & Cella, D. (2000). Validity and selectivity of the FACT/GOG-Ntx [Abstract 1751]. Proceedings of the American Society of Clinical Oncology. Retrieved April 7, 2008, from…
    Cavaletti, G., Boglium, F., Marzorati, L., Zincone, A., Piatti, M., Colombo, N., et al. (2003). Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale. Neurology, 61(9), 1297-1300.
    Celgene Corporation. (2007a). Revlimid® (lenalidomide) [Package insert]. Summit, NJ: Author.
    Celgene Corporation. (2007b). Thalomid® (thalidomide) [Package insert]. Summit, NJ: Author.
    Cella, D. F. (1997). FACIT: Functional Assessment of Cancer Therapy. Retrieved September 24, 2007, from
    Cella, D. F., Tulsky, D. S., Gray, G., Serafian, B., Linn, E., Bonomi, A., et al. (1993). The Functional Assessment of Cancer Therapy Scale: Development and validation of the general measure. Journal of Clinical Oncology, 11(3), 570-579.
    Colson, K., Doss, D. S., Swift, R., Tariman, J., & Thomas, T. E. (2004). Bortezomib, a newly approved proteasome inhibitor for the treatment of multiple myeloma: Nursing implications. Clinical Journal of Oncology Nursing, 8(5), 473-480.
    Cornblath, D. B., Chaudhry, V., Carter, K., Lee, D., Seysedadr, M., Miernicki, M., et al. (1999). Total Neuropathy Score. Validation and reliability study. Neurology, 53(8), 1660-1664.
    Shah, M. H., Young, D., Kindler, H. L., Webb, I., Kleiber, B., Wright, J., et al. (2004). Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors. Clinical Cancer Research, 10(18, Pt. 1), 6111-6118.
    Singhal, S., & Mehta, J. (2001). Thalidomide in cancer: Potential uses and limitations. BioDrugs, 15(3), 163-172.
    Sweeney, C. (2002). Understanding peripheral neuropathy in patients with cancer: Background and patient assessment. Clinical Journal of Oncology Nursing, 6(3), 163-166.
    Tariman, J. D. (2003). Thalidomide: Current therapeutic uses and management of its toxicities. Clinical Journal of Oncology Nursing, 7(2), 143-147.
    Tariman, J. D. (2005). Multiple myeloma. In C. H. Yarbro, M. H. Frogge, & M. Goodman (Eds.), Cancer nursing: Principles and practice (6th ed., pp. 1460-1489). Sudbury, MA: Jones and Bartlett.
    Tosi, P., Zamagni, E., Cellini, C., Plasmati, R., Cangini, D., Tacchetti, P., et al. (2005). Neurological toxicity of long-term (> 1 yr) thalidomide therapy in patients with multiple myeloma. European Journal of Haematology, 74(3), 212-216.
    Visovsky, C., Collins, M. L., Hart, C., Abbott, L. I., & Aschenbrenner, J. A. (2007). Oncology Nursing Society Putting Evidence Into Practice®: Peripheral neuropathy. Retrieved October 19, 2007, from
    Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., et al. (2007). Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. New England Journal of Medicine, 357(21), 2133-2142.
    Wickham, R. (2007). Chemotherapy-induced peripheral neuropathy: A review and implications for oncology nursing practice. Clinical Journal of Oncology Nursing, 11(3), 361-376.
    Rajkumar, S. V., Hayman, S. R., Lacy, M. Q., Dispenzieri, A., Geyer, S. M., Kabat, B., et al. (2005). Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood, 106(13), 4050-4053.